4D pharma (LON:DDDD) Shares Up 5%
4D pharma (LON:DDDD) Shares Up 5%
Shares of 4D pharma plc (LON:DDDD – Get Rating) shot up 5% on Monday . The company traded as high as GBX 16.86 ($0.21) and last traded at GBX 16.66 ($0.20). 912,370 shares were traded during mid-day trading, a decline of 69% from the average session volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).
週一，4D Pharma plc（LON: DDDD — 獲取評級）的股價飆升了5％。該公司的交易價格高達16.86英鎊（0.21美元），最後一次交易價格爲16.66英鎊（0.20美元）。午盤交易中交易了912,370股，較平均交易日2,957,490股下跌了69％。該股此前收於15.86英鎊（0.19美元）。
4D pharma Stock Performance
4D 製藥股票表現
The company has a debt-to-equity ratio of 39.50, a quick ratio of 4.72 and a current ratio of 5.21. The stock has a market cap of £30.04 million and a price-to-earnings ratio of -1.08. The stock has a fifty day simple moving average of GBX 21.66 and a two-hundred day simple moving average of GBX 32.26.
該公司的負債權益比率爲39.50，速動比率爲4.72，流動比率爲5.21。該股的市值爲3,0004萬英鎊，市盈率爲-1.08。該股的五十天簡單移動平均線爲21.66英鎊，兩百天簡單移動平均線爲32.26英鎊。
4D pharma Company Profile
4D 製藥公司簡介
(Get Rating)
（獲取評級）
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.
4D pharma plc及其子公司在英國開發活生物治療產品（LBP）。該公司開發候選治療藥物，包括用於治療癌症和免疫腫瘤學疾病的mrx0518；用於治療哮喘的mrx-4dp0004；治療中樞神經系統疾病的mrx0029和mrx0005；治療腸易激綜合徵的Blautix；以及用於小兒克羅恩病的Thetanix。
Recommended Stories
推薦故事
- AutoNation Stock is Firing on All Pistons
- Caterpillar Falls To Strong Support Near Bottom Of Range
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- AutoNation Stock 正在向所有活塞開火
- 卡特彼勒跌至區間底部附近的強勁支撐
- AMD 第二季度收益大幅超出預期，AMD 值得買入嗎？
- 金融健康狀況良好的3只醫療保健股
- 亞馬遜將自己列爲第三季度競爭者的頭號股票
Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收4D Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收4D製藥及相關公司最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。